Compare CHMG & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHMG | REPL |
|---|---|---|
| Founded | 1833 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.1M | 407.1M |
| IPO Year | 1995 | 2018 |
| Metric | CHMG | REPL |
|---|---|---|
| Price | $76.50 | $9.97 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 9 |
| Target Price | ★ $57.00 | $5.67 |
| AVG Volume (30 Days) | 43.8K | ★ 3.2M |
| Earning Date | 04-17-2026 | 05-21-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $37.32 | N/A |
| Revenue Next Year | $9.13 | N/A |
| P/E Ratio | $40.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $48.61 | $1.50 |
| 52 Week High | $78.10 | $13.24 |
| Indicator | CHMG | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 61.71 | 51.68 |
| Support Level | $72.35 | $9.69 |
| Resistance Level | $76.68 | $10.71 |
| Average True Range (ATR) | 2.21 | 0.76 |
| MACD | 0.03 | -0.36 |
| Stochastic Oscillator | 74.49 | 32.59 |
Chemung Financial Corp is a bank holding firm. Through its subsidiaries, the company provides various financial services, including demand, savings, and time deposits, commercial, residential, and consumer loans, letters of credit, wealth management services, employee benefit plans, insurance products, mutual funds, and brokerage services, among others. The company's reportable segments are Core Banking, Wealth Management (WMG) services, and Holding company and CFS. Maximum revenue is generated from the Core Banking segment, which derives revenue by attracting deposits from the general public and using such funds to originate different types of loans, and to invest in securities. The Wealth Management (WMG) services segment provides trust and investment advisory services to clients.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.